Oxurion

What Oxurion does

Oxurion NV (Euronext Brussels: OXUR; ISIN BE0974487192) is a Belgian holding company that has pivoted from ophthalmic drug development (originally ThromboGenics NV) to building a pan-European clinical research organization (CRO) platform through a buy-and-build consolidation strategy. Following the clinical failure of its THR-149 and THR-687 retinal therapy candidates, the company rebranded in 2024 and began acquiring specialist CROs across the clinical research value chain — covering biometrics, clinical data management, biostatistics, regulatory submissions, medical writing, clinical operations, and pharmacovigilance. The operating core is Axiodis SAS, a French CRO acquired with a 72% controlling stake in 2024, which serves biotech, pharmaceutical, medtech, and academic sponsors running complex Phase II/III studies across 12+ European countries and 7,000+ patient files.

The company's proprietary technology is Exagis, a next-generation Clinical Data Management System (CDMS) and electronic Case Report Form (eCRF) platform developed internally since 2012 through Axiodis. Exagis is purpose-built for biometrics-heavy studies and ships with modules covering eCRF design (standard setup in 5 business days), end-to-end data management, MedDRA/WHO-Drug coding, centralized query management, CDISC-compliant CDASH data collection and SDTM export for EMA/FDA submissions, patient-reported outcomes (ePRO) via browser without app install, real-time sponsor dashboards, and HDS-certified server hosting in France. The most recent module, the electronic Trial Master File (eTMF) for clinical trial documentation, launched commercially in July 2026. An AI-assisted validation and virtual-patient roadmap is publicly disclosed but not yet shipped.

Oxurion generates revenue through two principal streams: project-based professional services from CRO engagements, and recurring subscription revenue from Exagis platform licensing and modules. The go-to-market is sales-led direct enterprise engagement, with CEO Pascal Ghoson serving as primary business development contact, supplemented by 20+ academic, biotech, and pharma partners. Pierre Fabre Laboratories is the most prominently cited enterprise customer win. The company is publicly listed in Belgium and is primarily funded through a EUR 20 million Capital Commitment from Atlas Special Opportunities LLC delivered as convertibles, which has driven significant shareholder dilution through 2023-2026.

Name

Oxurion

Legal name

Oxurion NV

Website

https://oxurion.com

Company type

Public

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

Oxurion NV is a Belgian holding company building a pan-European clinical research organization (CRO) platform through a buy-and-build strategy, anchored by its 72%-owned French subsidiary Axiodis SAS and the proprietary Exagis CDMS platform serving biotech, pharma, medtech, and academic sponsors.

Ownership category

akta.pro rank

Product category

Clinical Research Organization Services

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

akta.pro secondary industries

Clinical CROs (Phase I–IV) (HLAGAAAA), Clinical Trial Informatics (EDC/CTMS/eCOA/eTMF) (HLAGAJAM)

Keywords

• Clinical research organization
• Clinical data management
• Biometrics and biostatistics
• Clinical trial software
• Regulatory submission services

Headquarters

HQ city

Heverlee

HQ country

Belgium

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. CRO Services Revenue: Clinical research organization services including biometrics, data management, biostatistics, regulatory submissions, medical writing, clinical operations, and pharmacovigilance. Revenue generated through project-based professional services contracts with biotech, pharmaceutical, medtech and academic sponsors.
2. Software Platform Revenue: Recurring software revenue from the Exagis CDMS platform, including eCRF, data management, and ePRO modules. Each successive platform module is expected to increase platform value, strengthen customer retention, and expand long-term recurring software revenue opportunities. Pierre Fabre Laboratories use of Exagis represents major market validation.
3. eTMF Module Revenue: Electronic Trial Master File module launched commercially in 2026 as part of the Exagis platform expansion. The eTMF serves as a secure digital repository for clinical trial documentation ensuring regulatory compliance, inspection readiness, and collaboration throughout study lifecycles.
4. Future AI-Assisted Services (Roadmap): Future roadmap includes AI-assisted study design, adaptive randomization optimization, and advanced analytics tools as part of the long-term strategy to build a comprehensive eClinical platform with recurring software revenue.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Oxurion sells clinical research organization (CRO) services and the proprietary Exagis CDMS platform. Through its 72%-owned subsidiary Axiodis CRO, it delivers biometrics, clinical data management, biostatistics, regulatory submissions, medical writing, clinical operations, and pharmacovigilance services to biotech, pharmaceutical, medtech and academic sponsors. The Exagis platform provides electronic Case Report Forms, data management, query management, CDISC-compliant SDTM export, ePRO, reporting dashboards, HDS-certified hosting, and the recently launched electronic Trial Master File (eTMF) module.

Product overview

Oxurion operates as a holding company building a leading European clinical research organization (CRO) group through a buy-and-build consolidation strategy. The company holds a 72% controlling stake in Axiodis CRO, a French specialist in biometrics and data management. The core technology is Exagis, a proprietary next-generation CDMS (Clinical Data Management System) platform that includes multiple modules: eCRF (electronic Case Report Form) for data collection, data management, query management, CDISC compliance (CDASH/SDTM), ePRO (patient-reported outcomes), reporting dashboards, HDS-certified hosting, and the recently launched eTMF (electronic Trial Master File) module. The Exagis platform is purpose-built for biometrics-heavy studies and supports multi-center international trials across 12+ European countries in 11 languages. The company offers full clinical data expertise including biometrics, biostatistics, regulatory submissions, medical writing, clinical operations, and pharmacovigilance services through Axiodis. The technology roadmap includes AI-assisted intelligent data validation and virtual patient technologies.

Differentiator

Problem solved

Functional benefit

Brands

• Axiodis CRO: French specialist in clinical biometrics and data management — the cornerstone of the Oxurion buy-and-build platform, offering biometrics, data management, biostatistics, regulatory submissions, medical writing, clinical operations, and pharmacovigilance services.
• Exagis CDMS

Products and services

• Exagis CDMS Platform Proprietary next-generation Clinical Data Management System (CDMS) and electronic Case Report Form (eCRF) platform built by biostatisticians for biometrics-heavy studies. Provides end-to-end data lifecycle management from eCRF design through database lock, supporting CDISC compliance (CDASH/SDTM), 11-language multilingual trials, medical coding (MedDRA/WHO-Drug), ePRO, real-time sponsor dashboards, and HDS-certified hosting. Delivered as SaaS for biotech, pharmaceutical, medtech and academic sponsors conducting complex multi-country Phase II/III studies.
• Axiodis CRO Services Full-service clinical research organization (CRO) services delivered through Axiodis SAS, a French specialist in clinical biometrics, clinical data management, biostatistics, regulatory submissions, medical writing, clinical operations, and pharmacovigilance. Acquired as 72% controlling stake; brings 15+ years of regulatory-grade biometrics expertise and runs the proprietary Exagis CDMS platform across complex studies for biotech, pharmaceutical, medtech and academic sponsors. Conducts 50+ studies per year across 12+ European countries with 7,000+ patient files processed.
• Exagis eTMF Module Electronic Trial Master File (eTMF) module of the Exagis platform serving as a secure digital repository for clinical trial documentation. Designed to ensure regulatory compliance, inspection readiness, and collaboration among stakeholders throughout the study lifecycle. Commercial launch as a distinct module of the Exagis eClinical platform.

Quantifiable outcome

• Standard eCRF setup in 5 business days
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability1 record

Feature10 records

Partnerships

Four partnerships are on record, tiered key, emerging and flagship.

• Pierre Fabre LaboratorieskeyTechnology or Integration · 15 June 2026Pierre Fabre Laboratories represent major market validation for the Exagis platform, demonstrating enterprise-level adoption by a major pharmaceutical company. This partnership validates the commercial viability of Oxurion's software-driven growth strategy and platform expansion roadmap.
• GLP-1 and Peptide Clinical Research PartnersemergingStrategic or Co-development Partner · 2 June 2026Oxurion expanded its capabilities to address growing demand for GLP-1 and peptide clinical research services. This represents an emerging partnership area targeting companies developing novel peptide-based therapeutics requiring specialized clinical research support.
• Axiodis SASflagshipStrategic or Co-development Partner · 1 January 2024Axiodis SAS is a French CRO specialized in biometrics, clinical data management and biostatistics. Acquired as a 72% controlling stake in 2024, it serves as the cornerstone of Oxurion's European CRO platform. The subsidiary operates the proprietary Exagis CDMS platform and brings 15+ years of regulatory-grade biometrics expertise.
• Academic, Biotech & Pharma Partners NetworkkeyStrategic or Co-development Partner · 1 January 2024Oxurion maintains an active network of 20+ academic, biotech and pharma partners. These partnerships support clinical study execution across multiple therapeutic areas and geographies. The network enables cross-selling opportunities across the integrated CRO platform.

Scale indicators9 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Medpace Holdings: Medpace is a mid-sized, science-driven CRO focused on Phase I-IV clinical development with strong therapeutic-area expertise and proprietary technology. Comparable to Oxurion as a similarly positioned mid-market CRO competing in the same sponsor segments with a hybrid services-plus-technology offering.
• Veeva Systems: Veeva offers Vault CTMS, Vault EDC, and eTMF as part of its clinical operations cloud, directly competing with Exagis CDMS modules. Comparable because Veeva's clinical applications target the same biopharma CDM/biometrics buyer and emphasize regulatory-grade, software-delivered trial data management.
• Clario: Clario provides clinical trial technology and endpoint data solutions, including EDC, eCOA, and imaging, for biopharma sponsors. Comparable to Oxurion because Clario combines proprietary software with clinical-data services in the same eClinical/biometrics space Oxurion targets with Exagis.
• BioAgilytix: BioAgilytix is a mid-sized, science-focused CRO specializing in bioanalytical and biomarker services supporting clinical trials. Comparable to Oxurion/Axiodis because both serve biotech and pharma sponsors with specialized biometrics and clinical data expertise rather than competing as full-service general CROs.
• PSI CRO: PSI is a privately held, mid-sized full-service CRO with strong European footprint. Comparable to Oxurion/Axiodis as a similarly sized European-headquartered CRO competing for the same biotech, pharma, and academic clinical-trial work.
• Worldwide Clinical Trials: Worldwide Clinical Trials is a mid-sized, science-focused CRO with deep biometrics and clinical-data expertise. Comparable to Oxurion as a similarly sized CRO that competes for the same Phase II/III biometrics, biostatistics, and CDM work from biotech and pharma sponsors.

Emerging players

• Castor EDC: Castor is a cloud-based EDC and ePRO platform purpose-built for clinical research, with growing adoption among academic and biotech sponsors. Comparable to Exagis because both target EDC/ePRO buyers with modern, configurable software for clinical data capture in international trials.

Broad incumbents

• IQVIA: IQVIA is the world's largest CRO with broad clinical, data, and technology capabilities. Comparable to Oxurion as a benchmark competitor in the same overall clinical research services and clinical-data software category, but with materially deeper scale and global reach.
• ICON plc: ICON is a top-tier global CRO offering full Phase I-IV services plus clinical technology post-PRA Health Sciences. Comparable to Oxurion as an incumbent in the same CRO market that competes for similar biotech and pharma clinical development work at much larger scale.
• Charles River Laboratories: Charles River provides CRO services, including biometrics and clinical data management, alongside broader discovery and safety assessment offerings. Comparable to Oxurion because its clinical-data/biometrics business overlaps directly with Exagis and Axiodis services.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/oxurion
• Xx.com/oxurion

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Subsidiaries1 record

Funding overview

Funding rounds12 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Oxurion